These findings—together with recent clinical data showing that ATM mutations are associated with response to the PARP inhibitor olaparib in prostate cancer patients [34]—support the further investigation of ATM protein level as a candidate predictive biomarker. Here, PARP1 is linked to prostate carcinoma.